Pfizer And Eisai Will Continue To Promote Aricept, But Add Lyrica To The Collaboration
This article was originally published in The Pink Sheet Daily
Executive Summary
After Eisai tried to get out of its co-promotion deal for the Alzheimer’s disease blockbuster, the two companies settle their dispute with Japanese rights to Aricept returning to Eisai sooner than originally planned.